Master Rollover Protocol for Continued Safety Assessment of Study Drug

Sponsor: Eli Lilly and Company

Expanded Access
Sponsor score: 60
Inactive

ClinicalTrials ID:NCT02632994

Patient View

This study allows patients who benefited from a previous Lilly study to continue receiving the study drug. Eligible patients must have participated in a concluded study with an open addendum. They cannot be in other incompatible research. Interventions include oral administration of LY2503029 and LY3023414.

Patient Parameters

Program Overview

This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.

Eligibility Criteria

Inclusion Criteria

  • To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.

Exclusion Criteria

  • Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

Get This Program In Your Inbox

You can sign up and apply your patients for this program.